-
1
-
-
46749146810
-
-
Williams Hematology, 7th ed McGraw-Hill, New York
-
Barlogie, B., Shaughnessy, J., Epstein, J., Sanderson, R., Anaissie, E., Walker, R. and Tricot, G. (2006) Plasma cell myeloma. Williams Hematology, 7th ed, pp. 1501-1533. McGraw-Hill, New York
-
(2006)
Plasma Cell Myeloma
, pp. 1501-1533
-
-
Barlogie, B.1
Shaughnessy, J.2
Epstein, J.3
Sanderson, R.4
Anaissie, E.5
Walker, R.6
Tricot, G.7
-
2
-
-
46749152626
-
-
Williams Hematology, 7th ed McGraw-Hill, New York
-
Jacobsen, D. R., Seldin, D. C. and Buxbaum, J. N. (2006) The amyloidoses. Williams Hematology, 7th ed, pp. 1535-1548. McGraw-Hill, New York
-
(2006)
The Amyloidoses
, pp. 1535-1548
-
-
Jacobsen, D.R.1
Seldin, D.C.2
Buxbaum, J.N.3
-
3
-
-
3042756207
-
Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myeloma
-
Ma, C. X., Lacy, M. Q., Rompala, J. F., Dispenzieri, A., Rajkumar, S. V. Greipp, P. R. et al. (2004) Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myeloma. Blood, 104, pp. 40-42.
-
(2004)
Blood
, vol.104
, pp. 40-42
-
-
Ma, C.X.1
Lacy, M.Q.2
Rompala, J.F.3
Dispenzieri, A.4
Rajkumar, S.V.5
Greipp, P.R.6
-
4
-
-
20644460600
-
International staging system for multiple myeloma
-
Greipp, P. R., San Miguel, J, Durie, B. G., Crowley, J. J., Barlogie, B. Blade, J. et al. (2005) International staging system for multiple myeloma. J Clin Oncol, 23, pp. 3412-3420.
-
(2005)
J Clin Oncol
, vol.23
, pp. 3412-3420
-
-
Greipp, P.R.1
San Miguel, J.2
Durie, B.G.3
Crowley, J.J.4
Barlogie, B.5
Blade, J.6
-
5
-
-
33644843725
-
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: Randomised controlled trial
-
Palumbo, A., Bringhen, S., Caravita, T., Merla, E., Capparella, V. Callea, V. et al. (2006) Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: Randomised controlled trial. Lancet, 367, pp. 825-831.
-
(2006)
Lancet
, vol.367
, pp. 825-831
-
-
Palumbo, A.1
Bringhen, S.2
Caravita, T.3
Merla, E.4
Capparella, V.5
Callea, V.6
-
6
-
-
0037110625
-
A phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients
-
Hussein, M. A., Wood, L., Hsi, E., Karam, M., Elson, P. and Bukowski, R. M. (2002) A phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients. Cancer, 95, pp. 2160-2168.
-
(2002)
Cancer
, vol.95
, pp. 2160-2168
-
-
Hussein, M.A.1
Wood, L.2
Hsi, E.3
Karam, M.4
Elson, P.5
Bukowski, R.M.6
-
7
-
-
0036839013
-
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma
-
Richardson, P. G., Schlossman, R. L., Weller, E., Hideshima, T., Mitsiades, C. Davies, F. et al. (2002) Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood, 100, pp. 3063-3067.
-
(2002)
Blood
, vol.100
, pp. 3063-3067
-
-
Richardson, P.G.1
Schlossman, R.L.2
Weller, E.3
Hideshima, T.4
Mitsiades, C.5
Davies, F.6
-
8
-
-
27744492561
-
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma
-
Rajkumar, S. V., Hayman, S. R., Lacy, M. Q., Dispenzieri, A., Geyer, S. M. Kabat, B. et al. (2005) Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood, 106, pp. 4050-4053.
-
(2005)
Blood
, vol.106
, pp. 4050-4053
-
-
Rajkumar, S.V.1
Hayman, S.R.2
Lacy, M.Q.3
Dispenzieri, A.4
Geyer, S.M.5
Kabat, B.6
-
9
-
-
33750607347
-
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma
-
Richardson, P. G., Blood, E., Mitsiades, C. S., Jagannath, S., Zeldenrust, S. R. Alsina, M. et al. (2006) A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 108, pp. 3458-3464.
-
(2006)
Blood
, vol.108
, pp. 3458-3464
-
-
Richardson, P.G.1
Blood, E.2
Mitsiades, C.S.3
Jagannath, S.4
Zeldenrust, S.R.5
Alsina, M.6
-
10
-
-
33846258025
-
The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis
-
Dispenzieri, A., Lacy, M. Q., Zeldenrust, S. R., Hayman, S. R., Kumar, S. K. Geyer, S. M. et al. (2007) The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood, 109, pp. 465-470.
-
(2007)
Blood
, vol.109
, pp. 465-470
-
-
Dispenzieri, A.1
Lacy, M.Q.2
Zeldenrust, S.R.3
Hayman, S.R.4
Kumar, S.K.5
Geyer, S.M.6
-
11
-
-
33846256126
-
Lenalidomide and dexamethasone in the treatment of AL amyloidosis: Results of a phase 2 trial
-
Sanchorawala, V., Wright, D. G., Rosenzweig, M., Finn, K. T., Fennessey, S. Zeldis, J. B. et al. (2007) Lenalidomide and dexamethasone in the treatment of AL amyloidosis: Results of a phase 2 trial. Blood, 109, pp. 492-496.
-
(2007)
Blood
, vol.109
, pp. 492-496
-
-
Sanchorawala, V.1
Wright, D.G.2
Rosenzweig, M.3
Finn, K.T.4
Fennessey, S.5
Zeldis, J.B.6
-
12
-
-
13444256401
-
Efficacy of lenalidomide in myelodysplastic syndromes
-
List, A., Kurtin, S., Roe, D. J., Buresh, A., Mahadevan, D. Fuchs, D. et al. (2005) Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med, 352, pp. 549-557.
-
(2005)
N Engl J Med
, vol.352
, pp. 549-557
-
-
List, A.1
Kurtin, S.2
Roe, D.J.3
Buresh, A.4
Mahadevan, D.5
Fuchs, D.6
-
13
-
-
33749438404
-
Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion
-
List, A., Dewald, G., Bennett, J., Giagounidis, A., Raza, A. Feldman, E. et al. (2006) Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med, 355, pp. 1456-1465.
-
(2006)
N Engl J Med
, vol.355
, pp. 1456-1465
-
-
List, A.1
Dewald, G.2
Bennett, J.3
Giagounidis, A.4
Raza, A.5
Feldman, E.6
-
14
-
-
3042734357
-
Aminoglycoside-associated severe renal failure in patients with multiple myeloma treated with thalidomide
-
Montagut, C., Bosch, F., Villela, L., Rosinol, L. and Blade, J. (2004) Aminoglycoside-associated severe renal failure in patients with multiple myeloma treated with thalidomide. Leuk Lymphoma, 45, pp. 1711-1712.
-
(2004)
Leuk Lymphoma
, vol.45
, pp. 1711-1712
-
-
Montagut, C.1
Bosch, F.2
Villela, L.3
Rosinol, L.4
Blade, J.5
-
15
-
-
0037359277
-
Tolerability and efficacy of thalidomide for treatment of patients with AL amyloidosis
-
Selden, D. C., Choufani, E. B., Dember, L. M., Wiesman, J., Berk, J. L. Falk, R. H. et al. (2003) Tolerability and efficacy of thalidomide for treatment of patients with AL amyloidosis. Clin Lymphoma, 3, pp. 241-246.
-
(2003)
Clin Lymphoma
, vol.3
, pp. 241-246
-
-
Selden, D.C.1
Choufani, E.B.2
Dember, L.M.3
Wiesman, J.4
Berk, J.L.5
Falk, R.H.6
-
16
-
-
15944395687
-
The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL)
-
Palladini, G., Perfetti, V., Perlini, S., Obici, L., Lavatelli, F. Caccialanza, R. et al. (2005) The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood, 105, pp. 2949-2951.
-
(2005)
Blood
, vol.105
, pp. 2949-2951
-
-
Palladini, G.1
Perfetti, V.2
Perlini, S.3
Obici, L.4
Lavatelli, F.5
Caccialanza, R.6
-
17
-
-
36148973115
-
Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis
-
Chen, N., Lau, H., Kong, L., Kumar, G., Zeldis, J. B. Knight, R. et al. (2007) Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J Clin Pharmacol, 47, pp. 1466-1475.
-
(2007)
J Clin Pharmacol
, vol.47
, pp. 1466-1475
-
-
Chen, N.1
Lau, H.2
Kong, L.3
Kumar, G.4
Zeldis, J.B.5
Knight, R.6
|